Amemiya H
National Children's Medical Research Center, Tokyo, Japan.
Artif Organs. 1996 Aug;20(8):832-5. doi: 10.1111/j.1525-1594.1996.tb04555.x.
15-Deoxyspargualin (DSG) is a synthetic analogue of spergualin isolated from the culture filtrate of Bacillus laterosporus. It shows a strong immunosuppressive effect by antiproliferating action inhibiting the IL-2-stimulated maturation of T cells from the G0/G1 phases to the S and G2/M phases. Hsc70, a constitutive member of Hsp70 was identified as the immunophilin of DSG by Nadlar et al. In allogeneic transplantation of rat heart and dog kidney, DSG was definitely proved to prevent rejection and to rescue ongoing rejection. Our multicenter clinical trials on DSG showed that the percent efficacy to reverse acute rejection was 70-80%, and 600 days graft survival was 90% in the cases effectively treated with DSG at acute rejections. The combined use of DSG with methylprednisolone to treat acute rejection and the use of DSG to treat rejections in chronic phases were reported as the beneficial uses of DSG.
15-脱氧司帕古林（DSG）是从侧孢芽孢杆菌培养滤液中分离出的司帕古林的合成类似物。它通过抑制白细胞介素-2刺激的T细胞从G0/G1期到S期和G2/M期的成熟的抗增殖作用，显示出强大的免疫抑制作用。热休克蛋白70家族成员之一的Hsc70被Nadlar等人鉴定为DSG的免疫亲和蛋白。在大鼠心脏和犬肾脏的同种异体移植中，DSG被明确证明可预防排斥反应并挽救正在发生的排斥反应。我们关于DSG的多中心临床试验表明，逆转急性排斥反应的有效率为70-80%，在急性排斥反应时接受DSG有效治疗的病例中，移植物600天存活率为90%。有报道称，DSG与甲基强的松龙联合用于治疗急性排斥反应以及DSG用于治疗慢性期排斥反应均为DSG的有益应用。
